Last reviewed · How we verify

NCT04993469: PROGAS

Patient Reported Outcome on Genital Sensitivity and Sexual Function After Genital Gender Affirming Surgery

Recruiting now NA Last updated 22 December 2023
What this trial tests

NA trial testing Semmes-Weinstein monofilament testing and questionnaires in Gender Dysphoria in 200 participants. Currently enrolling.

Timeline
27 May 2021
Primary endpoint
31 December 2030
31 December 2030

Quick facts

Lead sponsorUniversity Hospital, Ghent
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment200
Start date27 May 2021
Primary completion31 December 2030
Estimated completion31 December 2030
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Ghent

Who can join

Adults 18 to 110, any sex, with Gender Dysphoria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For genital gender affirming surgery, it remains unclear to what extent genital sensitivity might be expected and what the impact of this might be on sexual functioning.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gender Dysphoria

Currently open trials in the same condition.

Other University Hospital, Ghent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04993469.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing